New drug CT-95 targets tough cancers in early trial
NCT ID NCT06756035
First seen Jun 07, 2026 · Last updated Jun 12, 2026 · Updated 3 times
Summary
This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesothelin-positive cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Context Investigational Site
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Context Investigational Site
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Context Investigational Site
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Context Investigational Site
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Context Investigational Site
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Context Investigational Site
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Context Investigational Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Context Investigational Site
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.